Upadacitinib (Rinvoq®) for psoriatic arthritis. HTA ID: 21040

Assessment Status Rapid review complete
HTA ID 21040
Drug Upadacitinib
Brand Rinvoq®
Indication For adults with active psoriatic arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs.
Assessment Process
Rapid review commissioned 01/09/2021
Rapid review completed 19/10/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that upadacitinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations February 2022.